The immunomodulatory role of MGL in cancer can be mediated by recognition of terminal GalNAc residues or the Tn antigen, which are expressed in a variety of tumour-associated proteins such as MUC1, carcinoembryonic antigen (CEA), cancer antigen 15-3 (CA15-3) and receptor tyrosine kinase c-Met, a protein that is involved in colorectal carcinogenesis, among others [196,197,198]. Here, MUC1 is linked to cancer.